Biotech, and bioprocessing more specifically, is a great place to be. But it's time for a new adventure.
Dec 1, 2010
By:
Laura Bush
Biotech, and bioprocessing more specifically, is a great place to be. But it's time for a new adventure.
|
China's regulators acknowledge the quality gap, and have a plan for steady improvement.
Nov 1, 2010
By:
Laura Bush
China's regulators acknowledge the quality gap, and have a plan for steady improvement.
|
Good leaders look beyond industry woes to focus on patients
Oct 1, 2010
By:
Laura Bush
Good leaders look beyond industry woes to focus on patients
|
Industry and regulators disagree over noncritical parameters
Oct 1, 2010
By:
Laura Bush
Industry and regulators disagree over noncritical parameters.
|
Sep 24, 2010
By:
Laura Bush
Amgen has issued Epogen and Procrit recall.
|
Sep 8, 2010
By:
Laura Bush
Regulators, Industry Disagree Over Noncritical Process Parameters at CMC Forum
|
The third holy grail of biosimilars: interchangeability.
Sep 1, 2010
By:
Laura Bush
The third holy grail of biosimilars: interchangeability.
|
Aug 23, 2010
By:
Laura Bush
ImClone, a subsidiary of Eli Lilly, has closed a manufacturing facility at its site in Branchburg, NJ, as originally reported by MyCentralJersey.com and confirmed by BioPharm International.
|
Regulatory relief requires that regulators trust companies to know what they are doing, and to do it—consistently.
Aug 1, 2010
By:
Laura Bush
Regulatory relief requires that regulators trust companies to know what they are doing, and to do it—consistently.
|
|
